These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 2201046

  • 1. Immune modifiers in the treatment of bladder cancer.
    Morales A.
    Prog Clin Biol Res; 1990; 350():25-33. PubMed ID: 2201046
    [No Abstract] [Full Text] [Related]

  • 2. [ BCG-immunotherapy and bladder cancer].
    Rischmann P.
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract] [Full Text] [Related]

  • 3. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E, Martínez-Piñeiro Lorenzo L, Martínez-Piñeiro Caramés JA, de la Peña Barthel JJ.
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [BCG therapy. Its role in the treatment of tumors of the bladder].
    Patard JJ, Chopin DK, Abbou CC.
    Ann Urol (Paris); 1995 Dec; 29(5):292-3. PubMed ID: 8638911
    [No Abstract] [Full Text] [Related]

  • 6. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA, Chin JL, Batislam E, Karlik SJ, Garcia B, Skamene E.
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Loco-regional immunotherapy for bladder cancer.
    Kuss R, Haertig A.
    Prog Clin Biol Res; 1984 Aug; 162B():321-33. PubMed ID: 6504902
    [No Abstract] [Full Text] [Related]

  • 10. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S, Matsui Y, Takahashi T, Nishiyama H, Ito N, Yamamoto S, Kamoto T, Ogawa O.
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [Abstract] [Full Text] [Related]

  • 11. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
    Dalbagni G.
    Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
    [No Abstract] [Full Text] [Related]

  • 12. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH, Frambach M, Deinert I, Brandau S, Jocham D, Böhle A.
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C, Minocchi L, Arecchi S, Nicolucci D, Porcelli C, D'orazi V, Greco L, Stio F, Martino G, Messinetti S.
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA.
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.